189 related articles for article (PubMed ID: 23811274)
1. CITED2 modulates estrogen receptor transcriptional activity in breast cancer cells.
Lau WM; Doucet M; Huang D; Weber KL; Kominsky SL
Biochem Biophys Res Commun; 2013 Jul; 437(2):261-6. PubMed ID: 23811274
[TBL] [Abstract][Full Text] [Related]
2. CITED2 in breast carcinoma as a potent prognostic predictor associated with proliferation, migration and chemoresistance.
Minemura H; Takagi K; Sato A; Takahashi H; Miki Y; Shibahara Y; Watanabe M; Ishida T; Sasano H; Suzuki T
Cancer Sci; 2016 Dec; 107(12):1898-1908. PubMed ID: 27627783
[TBL] [Abstract][Full Text] [Related]
3. Identification of the CREB-binding protein/p300-interacting protein CITED2 as a peroxisome proliferator-activated receptor alpha coregulator.
Tien ES; Davis JW; Vanden Heuvel JP
J Biol Chem; 2004 Jun; 279(23):24053-63. PubMed ID: 15051727
[TBL] [Abstract][Full Text] [Related]
4. CITED2 is a novel direct effector of peroxisome proliferator-activated receptor γ in suppressing hepatocellular carcinoma cell growth.
Cheung KF; Zhao J; Hao Y; Li X; Lowe AW; Cheng AS; Sung JJ; Yu J
Cancer; 2013 Mar; 119(6):1217-26. PubMed ID: 23212831
[TBL] [Abstract][Full Text] [Related]
5. Post-transcriptional control of Cited2 by transforming growth factor beta. Regulation via Smads and Cited2 coding region.
Chou YT; Yang YC
J Biol Chem; 2006 Jul; 281(27):18451-62. PubMed ID: 16675452
[TBL] [Abstract][Full Text] [Related]
6. Expression of sex steroid receptors and their co-factors in normal and malignant breast tissue: AIB1 is a carcinoma-specific co-activator.
Hudelist G; Czerwenka K; Kubista E; Marton E; Pischinger K; Singer CF
Breast Cancer Res Treat; 2003 Mar; 78(2):193-204. PubMed ID: 12725419
[TBL] [Abstract][Full Text] [Related]
7. Human CREB-binding protein/p300-interacting transactivator with ED-rich tail (CITED) 4, a new member of the CITED family, functions as a co-activator for transcription factor AP-2.
Bragança J; Swingler T; Marques FI; Jones T; Eloranta JJ; Hurst HC; Shioda T; Bhattacharya S
J Biol Chem; 2002 Mar; 277(10):8559-65. PubMed ID: 11744733
[TBL] [Abstract][Full Text] [Related]
8. Knockdown of Cbp/P300-interacting transactivator with Glu/Asp-rich carboxy-terminal domain 2 inhibits cell division and increases apoptosis in gastric cancer.
Tang Z; He G; Xu J; Zhongfu L
J Surg Res; 2017 May; 211():1-7. PubMed ID: 28501104
[TBL] [Abstract][Full Text] [Related]
9. CITED2 functions as a molecular switch of cytokine-induced proliferation and quiescence.
Chou YT; Hsieh CH; Chiou SH; Hsu CF; Kao YR; Lee CC; Chung CH; Wang YH; Hsu HS; Pang ST; Shieh YS; Wu CW
Cell Death Differ; 2012 Dec; 19(12):2015-28. PubMed ID: 22814619
[TBL] [Abstract][Full Text] [Related]
10. p300 Modulates the BRCA1 inhibition of estrogen receptor activity.
Fan S; Ma YX; Wang C; Yuan RQ; Meng Q; Wang JA; Erdos M; Goldberg ID; Webb P; Kushner PJ; Pestell RG; Rosen EM
Cancer Res; 2002 Jan; 62(1):141-51. PubMed ID: 11782371
[TBL] [Abstract][Full Text] [Related]
11. Physical and functional interactions among AP-2 transcription factors, p300/CREB-binding protein, and CITED2.
Bragança J; Eloranta JJ; Bamforth SD; Ibbitt JC; Hurst HC; Bhattacharya S
J Biol Chem; 2003 May; 278(18):16021-9. PubMed ID: 12586840
[TBL] [Abstract][Full Text] [Related]
12. CITED2 and NCOR2 in anti-oestrogen resistance and progression of breast cancer.
van Agthoven T; Sieuwerts AM; Veldscholte J; Meijer-van Gelder ME; Smid M; Brinkman A; den Dekker AT; Leroy IM; van Ijcken WF; Sleijfer S; Foekens JA; Dorssers LC
Br J Cancer; 2009 Dec; 101(11):1824-32. PubMed ID: 19904269
[TBL] [Abstract][Full Text] [Related]
13. Cited2 modulates TGF-beta-mediated upregulation of MMP9.
Chou YT; Wang H; Chen Y; Danielpour D; Yang YC
Oncogene; 2006 Sep; 25(40):5547-60. PubMed ID: 16619037
[TBL] [Abstract][Full Text] [Related]
14. CBP/p300-interacting transactivator, with Glu/Asp-rich C-terminal domain, 2, and pre-B-cell leukemia transcription factor 1 in human adrenal development and disease.
Ferraz-de-Souza B; Martin F; Mallet D; Hudson-Davies RE; Cogram P; Lin L; Gerrelli D; Beuschlein F; Morel Y; Huebner A; Achermann JC
J Clin Endocrinol Metab; 2009 Feb; 94(2):678-83. PubMed ID: 18984668
[TBL] [Abstract][Full Text] [Related]
15. Expression levels of estrogen receptor-alpha, estrogen receptor-beta, coactivators, and corepressors in breast cancer.
Kurebayashi J; Otsuki T; Kunisue H; Tanaka K; Yamamoto S; Sonoo H
Clin Cancer Res; 2000 Feb; 6(2):512-8. PubMed ID: 10690532
[TBL] [Abstract][Full Text] [Related]
16. The transcription factor Vezf1 represses the expression of the antiangiogenic factor Cited2 in endothelial cells.
AlAbdi L; He M; Yang Q; Norvil AB; Gowher H
J Biol Chem; 2018 Jul; 293(28):11109-11118. PubMed ID: 29794136
[TBL] [Abstract][Full Text] [Related]
17. Identification of prospective factors promoting osteotropism in breast cancer: a potential role for CITED2.
Lau WM; Weber KL; Doucet M; Chou YT; Brady K; Kowalski J; Tsai HL; Yang J; Kominsky SL
Int J Cancer; 2010 Feb; 126(4):876-84. PubMed ID: 19642106
[TBL] [Abstract][Full Text] [Related]
18. CITED2 attenuates macrophage recruitment concordant with the downregulation of CCL20 in breast cancer cells.
Jayaraman S; Doucet M; Kominsky SL
Oncol Lett; 2018 Jan; 15(1):871-878. PubMed ID: 29399152
[TBL] [Abstract][Full Text] [Related]
19. The N-terminal of the estrogen receptor (ERalpha) mediates transcriptional cross-talk with the retinoic acid receptor in human breast cancer cells.
Rousseau C; Pettersson F; Couture MC; Paquin A; Galipeau J; Mader S; Miller WH
J Steroid Biochem Mol Biol; 2003 Jul; 86(1):1-14. PubMed ID: 12943740
[TBL] [Abstract][Full Text] [Related]
20. A fusion protein of the estrogen receptor (ER) and nuclear receptor corepressor (NCoR) strongly inhibits estrogen-dependent responses in breast cancer cells.
Chien PY; Ito M; Park Y; Tagami T; Gehm BD; Jameson JL
Mol Endocrinol; 1999 Dec; 13(12):2122-36. PubMed ID: 10598586
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
